Hoffman Michael B — SEC insider filings
SEC reporting owner CIK 1290208. 22 insider filings on record with FilingPulse; latest filed 2026-11-06.
Transaction summary — filings shown
Covers all 22 filings on record, filed 2020-08-31 to 2026-11-06. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 19 legs across 9 filings — 6,924,154 shares, $9,256,876 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 2 legs across 1 filing — 184,368 shares, $50,130 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 25.
- Largest priced transaction: purchase of 5,000,000 shares @ $1.00 ($5,000,000) in Annovis Bio, Inc., filed 2026-11-06.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Annovis Bio, Inc. (ANVS) | Director | 20 | 19 legs · 6,924,154 sh · $9,256,876 | — | 24 |
| Onconova Therapeutics, Inc. (ONTX) | Director | 1 | — | 2 legs · 184,368 sh · $50,130 | — |
| Translational Development Acquisition Corp. (TDAC) | Chairman and CEO, Director | 1 | — | — | 1 |
Insider filings — Hoffman Michael B
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-06 | 4 | Annovis Bio, Inc. (ANVS) | Purchase (P): 5,000,000 @ $1 · Purchase (P): 5,000,000 (derivative) @ $0 | EDGAR |
| 2026-05-29 | 4 | Translational Development Acquisition Corp. (TDAC) | Purchase (P): 53,395 (derivative) @ $0.79 | EDGAR |
| 2026-05-21 | 4 | Annovis Bio, Inc. (ANVS) | Purchase (P): 2,562 @ $1.75 · Purchase (P): 18,849 @ $1.80 · Purchase (P): 54,933 @ $1.90 | EDGAR |
| 2026-04-03 | 4 | Annovis Bio, Inc. (ANVS) | Purchase (P): 713,800 @ $2.10 | EDGAR |
| 2025-12-08 | 4 | Annovis Bio, Inc. (ANVS) | Purchase (P): 30,000 @ $4.34 · Purchase (P): 15,000 @ $4.24 | EDGAR |
| 2025-11-25 | 4/A | Annovis Bio, Inc. (ANVS) | Purchase (P): 1,489 @ $4.13 · Purchase (P): 9,200 @ $3.85 · Purchase (P): 415 @ $4.14 · Purchase (P): 28,096 @ $4.15 | EDGAR |
| 2025-11-25 | 4 | Annovis Bio, Inc. (ANVS) | Purchase (P): 1,489 @ $4.13 · Purchase (P): 9,200 @ $3.85 · Purchase (P): 415 @ $4.14 · Purchase (P): 28,096 @ $4.15 | EDGAR |
| 2025-11-21 | 4 | Annovis Bio, Inc. (ANVS) | Purchase (P): 10,000 @ $3.49 · Purchase (P): 10,000 @ $3.50 | EDGAR |
| 2025-11-18 | 4 | Annovis Bio, Inc. (ANVS) | Purchase (P): 15,000 @ $2.11 | EDGAR |
| 2025-11-12 | 4 | Annovis Bio, Inc. (ANVS) | Purchase (P): 975,610 @ $2.05 | EDGAR |
| 2025-09-03 | 4 | Annovis Bio, Inc. (ANVS) | Grant/award (A): 5,000 @ $2.28 · Grant/award (A): 5,000 @ $2.29 · Grant/award (A): 5,000 @ $2.30 | EDGAR |
| 2025-08-20 | 4 | Annovis Bio, Inc. (ANVS) | Grant/award (A): 6,717 @ $2.60 · Grant/award (A): 5,283 @ $2.59 · Grant/award (A): 5,545 @ $2.58 · Grant/award (A): 1,100 @ $2.57 | EDGAR |
| 2025-06-16 | 4 | Annovis Bio, Inc. (ANVS) | Grant/award (A): 25,000 @ $2.80 · Grant/award (A): 1 @ $2.83 | EDGAR |
| 2025-06-02 | 4 | Annovis Bio, Inc. (ANVS) | Grant/award (A): 5,000 @ $2.43 | EDGAR |
| 2024-07-03 | 4 | Annovis Bio, Inc. (ANVS) | Grant/award (A): 29,600 (derivative) @ $0 | EDGAR |
| 2023-11-22 | 4/A | Annovis Bio, Inc. (ANVS) | Grant/award (A): 163,880 @ $6.10 | EDGAR |
| 2023-11-21 | 4 | Annovis Bio, Inc. (ANVS) | Grant/award (A): 164,745 @ $6.07 | EDGAR |
| 2023-04-11 | 4 | Annovis Bio, Inc. (ANVS) | Grant/award (A): 59,477 @ $12.61 | EDGAR |
| 2023-01-20 | 4 | Annovis Bio, Inc. (ANVS) | Grant/award (A): 6,820 (derivative) @ $0 | EDGAR |
| 2022-01-05 | 4 | Annovis Bio, Inc. (ANVS) | Option exercise (M): 30,000 @ $4.39 · Tax withholding (F): 6,658 @ $19.78 · Option exercise (M): 7,142 @ $0.25 · Tax withholding (F): 90 @ $19.78 · Grant/award (A): 9,000 (derivative) @ $0 · Option exercise (M): 30,000 (derivative) @ $0 · +1 more | EDGAR |
| 2021-07-09 | 4 | Annovis Bio, Inc. (ANVS) | Grant/award (A): 4,500 (derivative) @ $0 | EDGAR |
| 2020-08-31 | 4 | Onconova Therapeutics, Inc. (ONTX) | Sale (S): 182,492 @ $0.27 · Sale (S): 1,876 @ $0.27 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-08-26 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1290208 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs